CG Invites Co., Ltd.

A083790

KR7083790006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-27 EDT			5-day change	1st Jan Change
2,590 ^KRW	+1.97%		0.00%	-6.67%

04-18	Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	CI
03-27	PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI

Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.

May 16, 2022 at 03:39 am

From April 1, 2022 to May 16, 2022, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 688,603 shares, representing 1.01% for KRW 4,503.53 million under the buyback announced on February 15, 2022.

Latest news about CG Invites Co., Ltd.

Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	04-17	CI
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	03-26	CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	03-17	CI
CG Invites Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period	01-24	CI
An unknown buyer cancelled the acquisition of 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc.	12-13	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	23-10-11	CI
Crystal Bio Sciences Co., Ltd announced that it has received KRW 10 billion in funding from CrystalGenomics Invites Co., LTD.	23-10-11	CI
CrystalGenomics Invites Co., LTD.(KOSDAQ:A083790) dropped from S&P Global BMI Index	23-08-24	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
CrystalGenomics, Inc. announced that it has received KRW 62.427998592 billion in funding from New Lake Invites Investment Co., Ltd., Osung Advanced Materials Co., Ltd.	23-06-01	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
An unknown buyer agreed to acquire approximately 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc for KRW 28 billion.	23-03-29	CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.	22-11-21	CI
CrystalGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
CrystalGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
CrystalGenomics, Inc. announced that it has received KRW 5.7075 billion in funding from Kumho HT, Inc	22-08-07	CI
CrystalGenomics, Inc. announced that it expects to receive KRW 5.7075 billion in funding from Kumho HT, Inc	22-07-28	CI
CrystalGenomics, Inc. announced that it has received KRW 21.9999994 billion in funding	22-06-23	CI
CrystalGenomics, Inc. announced that it expects to receive KRW 21.9999994 billion in funding	22-06-12	CI
CrystalGenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.	22-05-16	CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.	22-05-16	CI
CrystalGenomics, Inc.'s Equity Buyback announced on February 15, 2022, has expired with 688,603 shares, representing 1.01% for KRW 4,503.53 million.	22-05-15	CI

Chart CG Invites Co., Ltd.

Duration

Period

More charts

Company Profile

CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CG INVITES CO., LTD.	-6.67%	143M
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B

Other Pharmaceuticals

CG Invites Co., Ltd.

Equities

A083790

KR7083790006

Pharmaceuticals

Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.

Latest news about CG Invites Co., Ltd.

Chart CG Invites Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals